REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that PrognomiQ has ...

Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease REDWOOD CITY, ...

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced the launch of the Seer ...

REDWOOD CITY, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the ...

Seasoned life sciences executive brings extensive global commercial leadership to accelerate growth and expand adoption of Seer’s Proteograph® ...

REDWOOD CITY - Seer, Inc. (NASDAQ:SEER) will present its proteomics technology at the 2026 U.S. Human Proteome Organization Annual Conference taking place February 21-25 in St. Louis, according to a ...

REDWOOD CITY, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced an expanded ...

Earnings call Seer reported Q4 2025 revenue of $4.2M (+5% YoY) and full-year revenue of $16.6M (+17% YoY), with 33% growth excluding related party revenue. Installed base grew 67% to 82 instruments.

New Seer Technology Access Center to open in Bonn, Germany Provides life sciences researchers conducting proteomic studies full-service access to the Seer Proteograph™ Product Suite and mass ...